Showing results (211-220 of 224) with videos related to

Sort By:
Pageof 23
International Braz J Urol : Official Journal of the Brazilian Society of Urology|February 5, 2026
Minimally Invasive Partial versus Radical Nephrectomy for Non-metastatic pT3a Renal Cell Carcinoma: a Multicenter Matched Cohort StudyXiangpeng Zou, Zhenhua Liu, Yunhan Luo, et al.
Cell Reports. Medicine|December 28, 2023
Extraperitonealization of the ileal conduit decreases the risk of parastomal hernia: A single-center, randomized clinical trialZhaohui Zhou, Longbin Xiong, Kai Yao, et al.
BMC Nephrology|July 9, 2016
RhoA deficiency disrupts podocyte cytoskeleton and induces podocyte apoptosis by inhibiting YAP/dendrin signalZongshun Huang, Li Zhang, Yuanhan Chen, et al.
European Radiology|December 20, 2022
Association of computed tomography-based body composition with survival in metastatic renal cancer patient received immunotherapy: a multicenter, retrospective studyJun Wang, Pei Dong, Yuanyuan Qu, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 20, 2024
First-Line PD-1 Blockade Combined With Chemotherapy for Stage IV Penile Squamous Cell Carcinoma: A Multicenter Retrospective StudyLongbin Xiong, Xingli Shan, Huali Ma, et al.
Elife|July 24, 2015
Genomic variations of the mevalonate pathway in porokeratosisZhenghua Zhang, Caihua Li, Fei Wu, et al.
Human Mutation|October 2, 2004
Fine mapping and identification of a candidate gene SSH1 in disseminated superficial actinic porokeratosisZhenghua Zhang, Zhenmin Niu, Wentao Yuan, et al.
Cell Communication and Signaling : CCS|July 2, 2026
A pan-cancer single-cell atlas uncovers the role of sex hormones and chromosomes in sex-divergent reprogramming of the tumor microenvironmentZhenyu Luo, Haoran Shi, Yingyi Shan, et al.
Frontiers in Medicine|December 22, 2025
Comparative study of eGFR in cancer and non-cancer individuals: a multicenter analysisBaokui Ye, Xin Luo, Yunhan Luo, et al.
Clinical & Translational Immunology|March 15, 2021
The efficacy and safety of the combination of axitinib and pembrolizumab-activated autologous DC-CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 studyMeng-Jia Song, Qiu-Zhong Pan, Ya Ding, et al.
Pageof 23